High burden of disease in young children with atopic dermatitis
The disease burden of atopic dermatitis is high in pediatric patients, according to new data presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
A team, led by Amy Paller, from Northwestern University Feinberg School of Medicine, has identified the true burden of atopic dermatitis in patients younger than 12.
The actual disease burden of moderate to severe atopic dermatitis in pediatric patients under 12 years of age is understudied and poorly defined.
Investigators used the ongoing 5-year, international, prospective, non-interventional PEDISTAD study to identify patients under 12 years of age with investigator-assessed moderate to severe atopic dermatitis inadequately controlled with topical therapies or patients for which such therapies are not recommended.
Each patient was assessed for various measures of disease burden reported at baseline, including physician-assessed eczema area and severity (EASO, 0-72) and body area affected by atopic dermatitis (BSA ), Patient-Oriented Eczema Reported by Patient/Caregiver Measure (POEM, 0-28), Infant’s Dermatitis Quality of Life (IDQOL,
There were 732 patients included in the study with a mean age of 6.2 years and a median age at onset of atopic dermatitis of 0.7 years. In addition, 59% of patients had type 2 inflammatory comorbidities.
Initial disease burden
Baseline data show a significant disease burden, with an average EASI of 14.4, 33.3% affected by BSA, a POEM score of 15.6, an IDQOL score of 10.3, a CDLQI score of 10 .8, worst scratching in 24 hours 5.9, worst nighttime itch 4.9, and worst daytime itch 3.8.
In addition, the frequency and proportion of patients reporting POEM features were itching > dry/rough skin > cracked skin > peeling skin > disturbed sleep > bleeding > crying/oozing.
The results were also similar across the different age groups – 0-1, 2-5, 5-11 – for the disease burden results.
“Children with moderate to severe AD aged less than 12 years in PEDISTAD had a significant disease burden, reflecting a major unmet need for effective disease control,” the authors wrote.
Pediatric patients with atopic dermatitis
Earlier this year, a new survey of pediatric patients with atopic dermatitis revealed increased β-glucocerebrosidase (GBA) activity in addition to increased glucosyl-cholesterol levels.
The new data suggest an association between increased GBA activity and inflammation in disrupted lipid processing.
Atopic dermatitis has been characterized by abnormalities in lipid organization along with immune dysregulations and an altered skin barrier, with researchers believing that altered GBA activity contributes to skin barrier defects in patients with atopic dermatitis.
The researchers observed that GBA activity was significantly higher in patients with atopic dermatitis at baseline compared to healthy controls, but decreased after 6 weeks of treatment.
The same pattern was observed with respect to glucosyl-cholesterol, as baseline values were higher in patients with atopic dermatitis compared to healthy controls and decreased after treatment.
However, glucosyl-cholesterol and GBA activity was still higher in patients with atopic dermatitis than in healthy controls, both of which correlated with transepidermal water loss and levels of several cytokines, including IL1α and IL-18.
The study, “The Patient Burden of Moderate-to-Severe Atopic Dermatitis (AD) in Aged Children,” was published online in the Journal of Allergy and Clinical Immunology.